March 29, 2023
Updates on MDRP NOTICE Release No. 117, Inflation Reduction Act Guidance...
5 Minute Read
Updates on MDRP NOTICE Release No. 117, Inflation Reduction Act, and Operationalizing Medicare Inflationary Rebates.
Blog
March 21, 2023
Perspectives on Pharma Market Access Launch Challenges & Strategy Part 2
9 Minute Read
We asked three market access leaders with significant launch experience across varying therapeutic categories about their launch journey–from pre-launch strategy and planning to post-launch optimization.
March 6, 2023
5 Pharma Gross-to-Net Questions You Should Be Asking
4 Minute Read
Whether manufacturers are entering new therapeutic categories, exploring new indications for a current product, or looking to acquire a new product through acquisition, managing Gross-To-Net can be complex.
February 27, 2023
FDA Set to Apply Orphan-Drug Exclusivity, 2022 Employer Health Benefits Survey...
5 Minute Read
Updates on two significant regulatory topics, including the FDA decision on orphan-drug exclusivity regulations and highlights from the Kaiser Family Foundation 2022 Employer Benefits Survey.
February 7, 2023
Perspectives on Pharma Market Access Launch Challenges & Strategy Part 1
5 Minute Read
We asked three market access leaders with significant launch experience across varying therapeutic categories about their launch journey–from pre-launch strategy and planning to post-launch optimization.
January 31, 2023
Inflation Reduction Act Impact on R&D, OIG Studies on Average Sales...
6 Minute Read
Updates on four significant regulatory topics, including the inflation reduction act impact on research and development, Office of Inspector General studies on Average Sales Price, and a shift of...
January 10, 2023
Direct Selling as a Distribution Channel for Specialty Lite Pharmaceuticals
3 Minute Read
Insights into specialty lite challenges and a new channel strategy that has emerged to help manufacturers balance patient access with their gross-to-net.
December 20, 2022
Value-Based Purchasing, Interchangeability in Biosimilars, Year End 2022 Roundup
5 Minute Read
Updates on two significant regulatory topics, including value-based purchasing, interchangeabilty with biosimilars, and an end of 2022 roundup.
December 15, 2022
2022 Trends in State Pricing Transparency Reporting
3 Minute Read
This is the first in a two-part blog series covering the ever-changing requirements by states as well as 2022 trends in Pricing Transparency Reporting.